Cleave Therapeutics
Cleave Therapeutics, a biopharmaceutical company, develops VCP/p97 inhibitors for cancer and neurodegenerative diseases, with a lead drug in clinical trials.
Cleave Therapeutics, a biopharmaceutical company, develops VCP/p97 inhibitors for cancer and neurodegenerative diseases, with a lead drug in clinical trials.
Cleave Therapeutics, founded with a mission to innovate treatments for cancer and neurodegenerative diseases, focuses on valosin-containing protein (VCP)/p97 as a novel therapeutic target. The company aims to address protein homeostasis and cellular stress pathways, developing VCP/p97 inhibitors. Their lead drug candidate is currently in clinical trials, targeting stress pathways in cancer cells. Cleave Therapeutics collaborates with the National Cancer Institute (NCI) and prominent academic institutions to advance its research and development efforts.
Notable figures affiliated with Cleave Therapeutics include leading scientists and researchers in the field of oncology and neurodegenerative diseases. The company has secured significant investment from prominent venture capital firms and has achieved key milestones, including successful preclinical studies and the initiation of clinical trials. Cleave Therapeutics' innovative approach has the potential to make a substantial impact on the treatment landscape for cancer and neurodegenerative conditions, addressing unmet medical needs through targeted protein inhibition.
Companies similar to Cleave Therapeutics include C4 Therapeutics, Claradele Pharmaceuticals, Innovo Therapeutics and CuraSen Therapeutics.
Cleave Therapeutics was founded in 2011.
Cleave Therapeutics' headquarters is located in San Francisco, CA, US.
Cleave Therapeutics' most recent funding round was for $12M (USD) in August 2019.
As of Aug 6, 2019, Cleave Therapeutics has raised a total of $101M (USD).
Cleave Therapeutics has 30 employees as of Feb 4, 2024.
Innovo Therapeutics
